These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 26282406)
1. Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours. Mellinas-Gomez M; Spanswick VJ; Paredes-Moscosso SR; Robson M; Pedley RB; Thurston DE; Baines SJ; Stell A; Hartley JA BMC Vet Res; 2015 Aug; 11():215. PubMed ID: 26282406 [TBL] [Abstract][Full Text] [Related]
2. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity. Hartley JA; Spanswick VJ; Brooks N; Clingen PH; McHugh PJ; Hochhauser D; Pedley RB; Kelland LR; Alley MC; Schultz R; Hollingshead MG; Schweikart KM; Tomaszewski JE; Sausville EA; Gregson SJ; Howard PW; Thurston DE Cancer Res; 2004 Sep; 64(18):6693-9. PubMed ID: 15374986 [TBL] [Abstract][Full Text] [Related]
3. γ-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000). Wu J; Clingen PH; Spanswick VJ; Mellinas-Gomez M; Meyer T; Puzanov I; Jodrell D; Hochhauser D; Hartley JA Clin Cancer Res; 2013 Feb; 19(3):721-30. PubMed ID: 23251007 [TBL] [Abstract][Full Text] [Related]
4. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations. Alley MC; Hollingshead MG; Pacula-Cox CM; Waud WR; Hartley JA; Howard PW; Gregson SJ; Thurston DE; Sausville EA Cancer Res; 2004 Sep; 64(18):6700-6. PubMed ID: 15374987 [TBL] [Abstract][Full Text] [Related]
5. DNA interstrand cross-linking and in vivo antitumor activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057. Hartley JA; Hamaguchi A; Suggitt M; Gregson SJ; Thurston DE; Howard PW Invest New Drugs; 2012 Jun; 30(3):950-8. PubMed ID: 21384134 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats. Reid JM; Buhrow SA; Kuffel MJ; Jia L; Spanswick VJ; Hartley JA; Thurston DE; Tomaszewski JE; Ames MM Cancer Chemother Pharmacol; 2011 Sep; 68(3):777-86. PubMed ID: 21188379 [TBL] [Abstract][Full Text] [Related]
7. Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent. Wilkinson GP; Taylor JP; Shnyder S; Cooper P; Howard PW; Thurston DE; Jenkins TC; Loadman PM Invest New Drugs; 2004 Aug; 22(3):231-40. PubMed ID: 15122070 [TBL] [Abstract][Full Text] [Related]
8. Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples. Spanswick VJ; Lowe HL; Newton C; Bingham JP; Bagnobianchi A; Kiakos K; Craddock C; Ledermann JA; Hochhauser D; Hartley JA BMC Cancer; 2012 Sep; 12():436. PubMed ID: 23020514 [TBL] [Abstract][Full Text] [Related]
9. Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling. Arnould S; Spanswick VJ; Macpherson JS; Hartley JA; Thurston DE; Jodrell DI; Guichard SM Mol Cancer Ther; 2006 Jun; 5(6):1602-9. PubMed ID: 16818520 [TBL] [Abstract][Full Text] [Related]
10. The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill. Pepper CJ; Hambly RM; Fegan CD; Delavault P; Thurston DE Cancer Res; 2004 Sep; 64(18):6750-5. PubMed ID: 15374993 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. Gregson SJ; Howard PW; Hartley JA; Brooks NA; Adams LJ; Jenkins TC; Kelland LR; Thurston DE J Med Chem; 2001 Mar; 44(5):737-48. PubMed ID: 11262084 [TBL] [Abstract][Full Text] [Related]
12. SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity. Hartley JA; Hamaguchi A; Coffils M; Martin CR; Suggitt M; Chen Z; Gregson SJ; Masterson LA; Tiberghien AC; Hartley JM; Pepper C; Lin TT; Fegan C; Thurston DE; Howard PW Cancer Res; 2010 Sep; 70(17):6849-58. PubMed ID: 20660714 [TBL] [Abstract][Full Text] [Related]
13. Preclinical pharmacology and antitumour activity of the novel sequence-selective DNA minor-groove cross-linking agent DSB-120. Walton MI; Goddard P; Kelland LR; Thurston DE; Harrap KR Cancer Chemother Pharmacol; 1996; 38(5):431-8. PubMed ID: 8765436 [TBL] [Abstract][Full Text] [Related]
14. Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors. Puzanov I; Lee W; Chen AP; Calcutt MW; Hachey DL; Vermeulen WL; Spanswick VJ; Liao CY; Hartley JA; Berlin JD; Rothenberg ML Clin Cancer Res; 2011 Jun; 17(11):3794-802. PubMed ID: 21346148 [TBL] [Abstract][Full Text] [Related]
15. Sequence-selective interaction of the minor-groove interstrand cross-linking agent SJG-136 with naked and cellular DNA: footprinting and enzyme inhibition studies. Martin C; Ellis T; McGurk CJ; Jenkins TC; Hartley JA; Waring MJ; Thurston DE Biochemistry; 2005 Mar; 44(11):4135-47. PubMed ID: 15766241 [TBL] [Abstract][Full Text] [Related]
16. ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies. Flynn MJ; Zammarchi F; Tyrer PC; Akarca AU; Janghra N; Britten CE; Havenith CE; Levy JN; Tiberghien A; Masterson LA; Barry C; D'Hooge F; Marafioti T; Parren PW; Williams DG; Howard PW; van Berkel PH; Hartley JA Mol Cancer Ther; 2016 Nov; 15(11):2709-2721. PubMed ID: 27535974 [TBL] [Abstract][Full Text] [Related]
17. Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells. Pepper C; Lowe H; Fegan C; Thurieau C; Thurston DE; Hartley JA; Delavault P Br J Cancer; 2007 Jul; 97(2):253-9. PubMed ID: 17579621 [TBL] [Abstract][Full Text] [Related]
18. Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors. Hochhauser D; Meyer T; Spanswick VJ; Wu J; Clingen PH; Loadman P; Cobb M; Gumbrell L; Begent RH; Hartley JA; Jodrell D Clin Cancer Res; 2009 Mar; 15(6):2140-7. PubMed ID: 19276288 [TBL] [Abstract][Full Text] [Related]
19. Anti-tumor effects of rivoceranib against canine melanoma and mammary gland tumour in vitro and in vivo mouse xenograft models. Li Q; Kim YS; An JH; Kwon JA; Han SH; Song WJ; Youn HY BMC Vet Res; 2021 Oct; 17(1):338. PubMed ID: 34702279 [TBL] [Abstract][Full Text] [Related]
20. The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136. Clingen PH; De Silva IU; McHugh PJ; Ghadessy FJ; Tilby MJ; Thurston DE; Hartley JA Nucleic Acids Res; 2005; 33(10):3283-91. PubMed ID: 15944449 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]